This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, P.-L.
Right arrow Articles by Seto, W.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, P.-L.
Right arrow Articles by Seto, W.-H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1999, p. 1310-1313, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong

Pak-Leung Ho,1,* Tak-Lun Que,2 Dominic Ngai-Chong Tsang,3 Tak-Keung Ng,4 Kin-Hung Chow,1 and Wing-Hon Seto5

Department of Microbiology, Division of Infectious Diseases, University of Hong Kong,1 Department of Microbiology, Queen Mary Hospital,5 Department of Pathology, Tuen Mun Hospital,2 Department of Microbiology, Queen Elizabeth Hospital,3 and Department of Microbiology, Princess Margaret Hospital,4 Hong Kong

Received 8 December 1998/Returned for modification 29 January 1999/Accepted 3 March 1999


    ABSTRACT
Top
Abstract
Text
References

The MICs of 17 antimicrobial agents for 181 Streptococcus pneumoniae strains were determined by the E-test. Overall, 69.1% were penicillin resistant (MIC > 0.06 µg/ml). Resistance to ciprofloxacin (MIC > 2 µg/ml), levofloxacin (MIC > 2 µg/ml), or trovafloxacin (MIC > 1 µg/ml) was found in 12.1, 5.5, or 2.2% of the strains, respectively. These high rates of resistance raise concerns for the future.


    TEXT
Top
Abstract
Text
References

The resistance of Streptococcus pneumoniae to beta -lactams, macrolides, tetracyclines, and chloramphenicol has been increasing rapidly in southeast Asia (1). Some of the newer fluoroquinolones, by virtue of their excellent in vitro activity against S. pneumoniae, oral bioavailability, and tissue penetration, hold promise as the drugs of choice for therapy of respiratory tract infections due to multiple drug-resistant S. pneumoniae in this region (6). We have therefore conducted a study on the in vitro activities of 3 fluoroquinolones and 13 other antimicrobial agents.

A total of 181 consecutive, nonduplicate isolates of S. pneumoniae were obtained from four regional laboratories (61 isolates from laboratory A, 41 isolates from laboratory B, 31 isolates from laboratory C, and 49 isolates from laboratory D) during the second half of 1998. These four laboratories provide microbiology service to seven public hospitals, serving a population of about 3 million in the Hong Kong island (south and west), Kowloon (central), and the New Territory (south and north) regions of Hong Kong. The strains were isolated from throat (5), nose (4), eye (5), sputum (143), tracheal aspirate (4), and blood (21). Strains were identified as S. pneumoniae by Gram stain, colony morphology, optochin susceptibility, and bile solubility.

The MICs of ciprofloxacin, levofloxacin, trovafloxacin, penicillin, ampicillin, ticarcillin-clavulanate, piperacillin-tazobactam, cefuroxime, cefpodoxime, ceftibuten, ceftriaxone, cefepime, meropenem, erythromycin, azithromycin, clindamycin, and vancomycin were determined by the E-test (AB Biodisk, Solna, Sweden) following the manufacturer's instructions. All susceptibility testings were done in the University of Hong Kong by one technician. Susceptibility tests were performed from a bacterial inoculum whose turbidity was equivalent to that of a McFarland standard of 0.5. From this suspension, E-tests were performed on Mueller-Hinton agar with 5% sheep blood (Micro Diagnostics Incorporated, Lombard, Ill.). The plates were incubated at 35°C in 5% CO2 for 20 to 24 h (10). MICs falling between two marks on the E-test strip were rounded up to the next higher twofold dilution, as recommended in the instructions. Quality control strains (S. pneumoniae ATCC 49619, Staphylococcus aureus ATCC 29213, and Escherichia coli ATCC 25922) were included with each run. Interpretation of results was performed according to recommendations of the National Committee for Clinical Laboratory Standards (NCCLS) (8). Because the NCCLS breakpoints for microbroth dilution appear to have limited applicability to E-test results for macrolides versus S. pneumoniae, modified breakpoints as recommended by the manufacturer were used (2). For erythromycin, the breakpoints were as follows: susceptible, <= 0.5 µg/ml; intermediate, 1 µg/ml; and resistant, >= 2 µg/ml. For azithromycin, the following breakpoints were used: susceptible, <= 4 µg/ml; intermediate, 8 µg/ml; and resistant, >= 16 µg/ml. No reference breakpoints for cefpodoxime, ceftibuten, ticarcillin-clavulanate, piperacillin-tazobactam, and ciprofloxacin are available. Multiple drug resistance is defined as resistance to at least one member from each of the three classes of antimicrobial agents including the beta -lactams, macrolides, and fluoroquinolones. The chi-square, Fisher exact, or Kruskal-Wallis test was used for statistical analysis.

The susceptibilities of the 181 pneumococcal isolates to 17 antimicrobial agents are summarized in Table 1. Rates of resistance to penicillin (MIC > 0.06 µg/ml) were 60.7% (37 of 61) for laboratory A, 80.5% (33 of 41) for laboratory B, 54.8% (17 of 31) for laboratory C, and 79.2% (38 of 48) for laboratory D (P = 0.05 for median MICs, Kruskal-Wallis test). Penicillin resistance rates were similar for children (age, <= 12 years) and adults (age, >12 years) (73.8 versus 66.4%, respectively; P > 0.05) but penicillin resistance was less common for blood isolates than for isolates from other sites (33.3 versus 73.8%, respectively; P < 0.01). Thirty-four (18.8%) isolates were highly resistant to penicillin with MICs of >2 µg/ml. For the most resistant isolate, the MIC was 6 µg/ml. The MICs of ampicillin and piperacillin-tazobactam for most strains were within one dilution difference of that of penicillin. However, the MIC of ticarcillin-clavulanate increased disproportionately with an increasing level of resistance to penicillin (data not shown). Ceftriaxone had the lowest MIC50 (MIC at which 50% of isolates were inhibited) and MIC90 among the cephalosporins, followed by cefepime, cefpodoxime, and cefuroxime. Multiple drug resistance was found in 12.1% (22 of 181) of the isolates.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Susceptibilities of 181 isolates of S. pneumoniae stratified by penicillin susceptibility

The distribution of MICs for the fluoroquinolones are shown in Fig. 1. Ciprofloxacin was the least active fluoroquinolone with a MIC of >2 µg/ml for 12.1% (22 of 181) of the isolates. Importantly, resistance to levofloxacin and trovafloxacin was only found in the penicillin-resistant isolates. Trovafloxacin was highly active, with similar MIC90s for both penicillin-susceptible and -resistant isolates. However, all four trovafloxacin-resistant isolates were also penicillin and macrolide resistant (Table 2).


View larger version (24K):
[in this window]
[in a new window]
  		FIG. 1.   Distribution of MICs of three fluoroquinolones for 181 strains of S. pneumoniae.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Distribution and MICs of four beta -lactam-macrolide-fluoroquinolone-resistant pneumococci

A marked increase in the overall prevalence of resistance to penicillin (69.1%) was found compared to rates from previous studies in 1993 (18%) and 1995 (28.9%) in Hong Kong (5, 7). While resistance to penicillin among S. pneumoniae isolates is an emerging problem worldwide, this high rate of resistance (>60%) has only been reported in several Asian countries, including Korea (73.4%), Taiwan (71%), Japan (67.7%), and Thailand (63.1%) (1, 12). High rates of cross-resistance to the cephalosporins (64 to 88%) and meropenem (80.2%) among the penicillin-intermediate or -resistant isolates were also found.

The overall rate of resistance to erythromycin also rose dramatically from 10% in 1993 and 39.2% in 1995 to 78.5% in the present study (3). The overall consumption of antimicrobial agents is frequently identified as a risk factor for the rapid emergence of resistance. Notably, the consumption of macrolides in Hong Kong increased by more than twofold from 1994 to 1997 (13). In addition, overcrowdedness may be another factor that contributes to the rapid dissemination of drug-resistant S. pneumoniae in Hong Kong. This is supported by findings from Ip and coworkers (6) that 70% of the penicillin-resistant strains belong to a variant of the Spanish type 23F clone.

The emergence of fluoroquinolone-resistant S. pneumoniae is alarming because this group of antimicrobial agents is at present the only possible option for oral therapy of infection due to beta -lactam-macrolide-resistant strains. Within 3 years, the rate of resistance to fluoroquinolones has increased from <0.5% for ofloxacin (5) to 5.5% for levofloxacin (MIC > 2 µg/ml). This is in contrast to the lack of development of resistance reported in other areas (2, 11, 14). Most alarming, 4% of the penicillin-resistant isolates were already highly resistant to trovafloxacin, an agent only registered for use in Hong Kong in October 1998.

In conclusion, we have reported extremely high rates of resistance to beta -lactams and macrolides among S. pneumoniae isolates in Hong Kong. Trovafloxacin is highly active in vitro against beta -lactam-macrolide-resistant strains. However, ominous resistance to fluoroquinolones is emerging. The global mobility of human populations and the convergence of tourist and business traffic in Hong Kong will likely facilitate the worldwide spread of these very resistant clones (7).


    ACKNOWLEDGMENTS

This study was supported by grants from the Committee on Research and Conference Grant, The University of Hong Kong, and the Pfizer Corporation, Hong Kong.

We thank Allan Ronald for a critical reading of the manuscript.


    FOOTNOTES

* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong. Phone: 852-2855 4897. Fax: 852-2855 1241. E-mail: plho{at}hkucc.hku.hk.


    REFERENCES
Top
Abstract
Text
References

1. Chiou, C. C., Y. C. Liu, T. S. Huang, W. K. Hwang, J. H. Wang, H. H. Lin, M. Y. Yen, and K. S. Hsieh. 1998. Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J. Clin. Microbiol. 36:1933-1937[Abstract/Free Full Text].
2. Cunha, B. A., S. M. Qadri, Y. Ueno, E. A. Walters, and P. Domenico. 1997. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J. Antimicrob. Chemother. 39(Suppl. B):29-34[Abstract/Free Full Text].
3. Fasola, E. L., S. Bajaksouzian, P. C. Appelbaum, and M. R. Jacobs. 1997. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob. Agents Chemother. 41:129-134[Abstract/Free Full Text].
4. Gerardo, S. H., D. M. Citron, M. C. Claros, and E. J. C. Goldstein. 1996. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob. Agents Chemother. 40:2413-2415[Abstract/Free Full Text].
5. Ho, P. L., K. Y. Yuen, W. C. Yam, S. S. Y. Wong, and W. K. Luk. 1995. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J. Hosp. Infect. 31:305-317[Medline].
6. Ip, M., D. J. Lyon, R. W. H. Yung, C. Chan, and A. F. Cheng. 1998. Molecular epidemiology of penicillin- and multidrug-resistant Streptococcus pneumoniae in Hong Kong, abstr. C20, p. 74. In Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Kam, K. M., K. Y. Luey, S. M. Fung, P. P. Yiu, T. J. Harden, and M. M. Cheung. 1995. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 39:2667-2670[Abstract/Free Full Text].
8. Klugman, K. P., and T. D. Gootz. 1997. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 39(Suppl. B):51-55[Abstract/Free Full Text].
9. Munoz, R., T. J. Coffey, M. Daniels, C. G. Dowson, G. Laible, J. Casal, et al. 1991. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J. Infect. Dis. 164:302-306[Medline].
10. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing, 8th informational supplement. M100-S8. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Plouffe, J. F. 1996. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group. Diagn. Microbiol. Infect. Dis. 25:43-45.
12. Song, J. H., and the Asian Network for Surveillance of Resistant Pneumococci (ANSORP) Study Group. 1997. Prevalence of drug-resistant pneumococci in 11 Asian countries, abstr. C48, p. 54. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Tam, C. Y. 1998. Extremely high rate of resistance to the macrolides in Hong Kong. Ming Pao Post 1998(Nov. 25):A2.
14. Thornsberry, C., P. Ogilvie, J. Kahn, and Y. Mauriz. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn. Microbiol. Infect. Dis. 29:249-257[Medline].

Antimicrobial Agents and Chemotherapy, May 1999, p. 1310-1313, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kosowska-Shick, K., Ednie, L. M., McGhee, P., Appelbaum, P. C. (2009). Comparative Antipneumococcal Activities of Sulopenem and Other Drugs. Antimicrob. Agents Chemother. 53: 2239-2247 [Abstract] [Full Text]  
  • Ho, P. L., Cheng, V. C., Chow, K. H. (2009). Decreasing prevalence of levofloxacin-resistant Streptococcus pneumoniae in Hong Kong, 2001 to 2007. J Antimicrob Chemother 63: 836-838 [Full Text]  
  • Page, S., Vernel-Pauillac, F., O'Connor, O., Bremont, S., Charavay, F., Courvalin, P., Goarant, C., Le Hello, S. (2008). Real-Time PCR Detection of gyrA and parC Mutations in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 52: 4155-4158 [Abstract] [Full Text]  
  • Clark, C., Smith, K., Ednie, L., Bogdanovich, T., Dewasse, B., McGhee, P., Appelbaum, P. C. (2008). In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci. Antimicrob. Agents Chemother. 52: 77-84 [Abstract] [Full Text]  
  • Gould, C. V., Sniegowski, P. D., Shchepetov, M., Metlay, J. P., Weiser, J. N. (2007). Identifying Mutator Phenotypes among Fluoroquinolone-Resistant Strains of Streptococcus pneumoniae Using Fluctuation Analysis. Antimicrob. Agents Chemother. 51: 3225-3229 [Abstract] [Full Text]  
  • Committee on Infectious Diseases, (2006). The Use of Systemic Fluoroquinolones. Pediatrics 118: 1287-1292 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Credito, K., Pankuch, G. A., Lin, G., Bozdogan, B., McGhee, P., Dewasse, B., Choi, D.-R., Ryu, J. M., Appelbaum, P. C. (2006). Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other Agents. Antimicrob. Agents Chemother. 50: 2064-2071 [Abstract] [Full Text]  
  • Lin, G., Smith, K., Ednie, L. M., Appelbaum, P. C. (2005). Antipneumococcal Activity of Dalbavancin Compared to Other Agents. Antimicrob. Agents Chemother. 49: 5182-5184 [Abstract] [Full Text]  
  • Jimenez, M. R. M., Bellido, J. L. M., Garcia Rodriguez, J. A. (2005). Risk Factors Associated with Colonization by Pneumococci with Reduced Susceptibility to Fluoroquinolones in Adult Outpatients. J. Clin. Microbiol. 43: 1193-1197 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G. (2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607 [Abstract] [Full Text]  
  • Morrissey, I., Tillotson, G. (2004). Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother 53: 144-148 [Abstract] [Full Text]  
  • Otsu, Y., Yanagihara, K., Fukuda, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J.-i., Tashiro, T., Murata, I., Kohno, S. (2003). In Vivo Efficacy of a New Quinolone, DQ-113, against Streptococcus pneumoniae in a Mouse Model. Antimicrob. Agents Chemother. 47: 3699-3703 [Abstract] [Full Text]  
  • Browne, F. A., Bozdogan, B., Clark, C., Kelly, L. M., Ednie, L., Kosowska, K., Dewasse, B., Jacobs, M. R., Appelbaum, P. C. (2003). Antipneumococcal Activity of DK-507k, a New Quinolone, Compared with the Activities of 10 Other Agents. Antimicrob. Agents Chemother. 47: 3815-3824 [Abstract] [Full Text]  
  • Canton, R., Morosini, M., Enright, M. C., Morrissey, I. (2003). Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 52: 944-952 [Abstract] [Full Text]  
  • Nilius, A. M., Shen, L. L., Hensey-Rudloff, D., Almer, L. S., Beyer, J. M., Balli, D. J., Cai, Y., Flamm, R. K. (2003). In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone. Antimicrob. Agents Chemother. 47: 3260-3269 [Abstract] [Full Text]  
  • Restrepo, M. I., Velez, J. A., McElmeel, M. L., Whitney, C. G., Jorgensen, J. H. (2003). Activity of Daptomycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 2974-2977 [Abstract] [Full Text]  
  • Schentag, J. J, Meagher, A. K, Forrest, A. (2003). Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models. The Annals of Pharmacotherapy 37: 1287-1298 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Davies, T. A., Goldschmidt, R., Pfleger, S., Loeloff, M., Bush, K., Sahm, D. F., Evangelista, A. (2003). Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 52: 168-175 [Abstract] [Full Text]  
  • Hsueh, P.-R., Teng, L.-J., Wu, T.-L., Yang, D., Huang, W.-K., Shyr, J.-M., Chuang, Y.-C., Wan, J.-H., Yan, J.-J., Lu, J.-J., Wu, J.-J., Ko, W.-C., Chang, F.-Y., Yang, Y.-C., Lau, Y.-J., Liu, Y.-C., Lee, C.-M., Leu, H.-S., Liu, C.-Y., Luh, K.-T. (2003). Telithromycin- and Fluoroquinolone-Resistant Streptococcus pneumoniae in Taiwan with High Prevalence of Resistance to Macrolides and {beta}-Lactams: SMART Program 2001 Data. Antimicrob. Agents Chemother. 47: 2145-2151 [Abstract] [Full Text]  
  • Karlowsky, J. A., Thornsberry, C., Critchley, I. A., Jones, M. E., Evangelista, A. T., Noel, G. J., Sahm, D. F. (2003). Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States. Antimicrob. Agents Chemother. 47: 1790-1797 [Abstract] [Full Text]  
  • Zhanel, G. G., Palatnick, L., Nichol, K. A., Bellyou, T., Low, D. E., Hoban, D. J. (2003). Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47: 1867-1874 [Abstract] [Full Text]  
  • Johnson, C. N., Benjamin, W. H. Jr., Moser, S. A., Hollingshead, S. K., Zheng, X., Crain, M. J., Nahm, M. H., Waites, K. B. (2003). Genetic Relatedness of Levofloxacin-Nonsusceptible Streptococcus pneumoniae Isolates from North America. J. Clin. Microbiol. 41: 2458-2464 [Abstract] [Full Text]  
  • Morrissey, I., Farrell, D. J., Bakker, S., Buckridge, S., Felmingham, D. (2003). Molecular Characterization and Antimicrobial Susceptibility of Fluoroquinolone-Resistant or -Susceptible Streptococcus pneumoniae from Hong Kong. Antimicrob. Agents Chemother. 47: 1433-1435 [Abstract] [Full Text]  
  • Ling, J. M., Lam, A. W., Chan, E. W., Cheng, A. F. (2003). What have we learnt from community-acquired infections in Hong Kong?. J Antimicrob Chemother 51: 895-904 [Abstract] [Full Text]  
  • Johnson, A. P., Warner, M., Nguyen-Van-Tam, J. S., Livermore, D. M. (2003). Activity of gemifloxacin against invasive and multi-resistant Streptococcus pneumoniae isolates collected in the UK. J Antimicrob Chemother 51: 188-190 [Full Text]  
  • Parry, C. M., Duong, N. M., Zhou, J., Mai, N. T. H., Diep, T. S., Thinh, L. Q., Wain, J., Van Vinh Chau, N., Griffiths, D., Day, N. P. J., White, N. J., Hien, T. T., Spratt, B. G., Farrar, J. J. (2002). Emergence in Vietnam of Streptococcus pneumoniae Resistant to Multiple Antimicrobial Agents as a Result of Dissemination of the Multiresistant Spain23F-1 Clone. Antimicrob. Agents Chemother. 46: 3512-3517 [Abstract] [Full Text]  
  • Yokota, S.-i., Sato, K., Kuwahara, O., Habadera, S., Tsukamoto, N., Ohuchi, H., Akizawa, H., Himi, T., Fujii, N. (2002). Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. 46: 3311-3315 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I. A., Karginova, E., Thornsberry, C., Sahm, D. F. (2002). Longitudinal Assessment of Antipneumococcal Susceptibility in the United States. Antimicrob. Agents Chemother. 46: 2651-2655 [Abstract] [Full Text]  
  • Peric, M., Lin, G., Clark, C. L., Jacobs, M. R., Appelbaum, P. C. (2002). Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents. J Antimicrob Chemother 50: 95-100 [Abstract] [Full Text]  
  • Klugman, K.P. (2002). Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 20: 3S-8s [Abstract] [Full Text]  
  • Ortqvist, A. (2002). Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J 20: 40S-53s [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Jacobs, M. R., Appelbaum, P. C. (2002). Effects of Amino Acid Alterations in Penicillin-Binding Proteins (PBPs) 1a, 2b, and 2x on PBP Affinities of Penicillin, Ampicillin, Amoxicillin, Cefditoren, Cefuroxime, Cefprozil, and Cefaclor in 18 Clinical Isolates of Penicillin-Susceptible, -Intermediate, and -Resistant Pneumococci. Antimicrob. Agents Chemother. 46: 1273-1280 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C.S., Kibsey, P., Fleming, C., Low, D. E. (2002). Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia. NEJM 346: 747-750 [Full Text]  
  • Brueggemann, A. B., Coffman, S. L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A., Flamm, R., Doern, G. V. (2002). Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46: 680-688 [Abstract] [Full Text]  
  • Betriu, C., Rodriguez-Avial, I., Sanchez, B. A., Gomez, M., Alvarez, J., Picazo, J. J. (2002). In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain. Antimicrob. Agents Chemother. 46: 892-895 [Abstract] [Full Text]  
  • Nagai, K., Appelbaum, P. C., Davies, T. A., Kelly, L. M., Hoellman, D. B., Andrasevic, A. T., Drukalska, L., Hryniewicz, W., Jacobs, M. R., Kolman, J., Miciuleviciene, J., Pana, M., Setchanova, L., Thege, M. K., Hupkova, H., Trupl, J., Urbaskova, P. (2002). Susceptibilities to Telithromycin and Six Other Agents and Prevalence of Macrolide Resistance Due to L4 Ribosomal Protein Mutation among 992 Pneumococci from 10 Central and Eastern European Countries. Antimicrob. Agents Chemother. 46: 371-377 [Abstract] [Full Text]  
  • Pankuch, G. A., Davies, T. A., Jacobs, M. R., Appelbaum, P. C. (2002). Antipneumococcal Activity of Ertapenem (MK-0826) Compared to Those of Other Agents. Antimicrob. Agents Chemother. 46: 42-46 [Abstract] [Full Text]  
  • Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D. E., Rubinstein, E., Wise, R., Consensus Group on Resistance and Prescribing in R, T. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 49: 31-40 [Abstract] [Full Text]  
  • Davies, T. A., Evangelista, A., Pfleger, S., Bush, K., Sahm, D. F., Goldschmidt, R. (2002). Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46: 119-124 [Abstract] [Full Text]  
  • Pankuch, G. A., Nagai, K., Davies, T. A., Jacobs, M. R., Appelbaum, P. C. (2002). Antipneumococcal Activity of BMS 284756 Compared to Those of Six Other Agents. Antimicrob. Agents Chemother. 46: 251-254 [Abstract] [Full Text]  
  • Weigel, L. M., Anderson, G. J., Facklam, R. R., Tenover, F. C. (2001). Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 3517-3523 [Abstract] [Full Text]  
  • Ho, P. L., Yung, R. W. H., Tsang, D. N. C., Que, T. L., Ho, M., Seto, W. H., Ng, T. K., Yam, W. C., Ng, W. W. S. (2001). Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 48: 659-665 [Abstract] [Full Text]  
  • Ho, P. L., Ng, T. K., Yung, R. W. H., Que, T. L., Yip, E. K. T., Tse, C. W. S., Yuen, K. Y. (2001). Activity of linezolid against levofloxacin-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in Hong Kong. J Antimicrob Chemother 48: 590-592 [Full Text]  
  • Chiu, S. S., Ho, P. L., Chow, F. K. H., Yuen, K. Y., Lau, Y. L. (2001). Nasopharyngeal Carriage of Antimicrobial-Resistant Streptococcus pneumoniae among Young Children Attending 79 Kindergartens and Day Care Centers in Hong Kong. Antimicrob. Agents Chemother. 45: 2765-2770 [Abstract] [Full Text]  
  • Alou, L., Ramirez, M., Garcia-Rey, C., Prieto, J., de Lencastre, H. (2001). Streptococcus pneumoniae Isolates with Reduced Susceptibility to Ciprofloxacin in Spain: Clonal Diversity and Appearance of Ciprofloxacin-Resistant Epidemic Clones. Antimicrob. Agents Chemother. 45: 2955-2957 [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2001). Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48: 365-374 [Abstract] [Full Text]  
  • Bast, D. J., de Azavedo, J. C. S., Tam, T. Y., Kilburn, L., Duncan, C., Mandell, L. A., Davidson, R. J., Low, D. E. (2001). Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 2631-2634 [Abstract] [Full Text]  
  • File, T. M. Jr, Schlemmer, B., Garau, J., Cupo, M., Young, C., the 049 Clinical Study Group, (2001). Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 48: 67-74 [Abstract] [Full Text]  
  • Thornsberry, C., Karlowsky, J. A., Sahm, D. F., Jorgensen, J. H., Weigel, L. M., Swenson, J. M., Whitney, C. G., Tenover, F. C., Ferraro, M. J. (2001). Levofloxacin-Resistant Streptococcus pneumoniae: Second Look. Antimicrob. Agents Chemother. 45: 2183-2184 [Full Text]  
  • Coyle, E. A., Kaatz, G. W., Rybak, M. J. (2001). Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1654-1659 [Abstract] [Full Text]  
  • Richardson, D. C., Bast, D., McGeer, A., Low, D. E. (2001). Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1911-1914 [Abstract] [Full Text]  
  • Ho, P. L., Yam, W. C., Que, T. L., Tsang, D. N. C., Seto, W. H., Ng, T. K., Ng, W. S. (2001). Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. J Antimicrob Chemother 47: 655-658 [Abstract] [Full Text]  
  • Sahm, D. F., Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Mauriz, Y., Kahn, J. (2001). Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis. Antimicrob. Agents Chemother. 45: 1037-1042 [Abstract] [Full Text]  
  • Coyle, E. A., Rybak, M. J. (2001). Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 45: 706-709 [Abstract] [Full Text]  
  • Cubbon, M. D., Masterton, R. G. (2000). New quinolones--a fresh answer to the pneumococcus. J Antimicrob Chemother 46: 869-872 [Full Text]  
  • Wright, D. H., Brown, G. H., Peterson, M. L., Rotschafer, J. C. (2000). Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46: 669-683 [Abstract] [Full Text]  
  • Kumarasinghe, G., Chow, C., Tambyah, P. A. (2000). The emergence of resistance to levofloxacin before clinical use in a university hospital in Singapore. J Antimicrob Chemother 46: 862-863 [Full Text]  
  • Jorgensen, J. H., Weigel, L. M., Swenson, J. M., Whitney, C. G., Ferraro, M. J., Tenover, F. C. (2000). Activities of Clinafloxacin, Gatifloxacin, Gemifloxacin, and Trovafloxacin against Recent Clinical Isolates of Levofloxacin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 2962-2968 [Abstract] [Full Text]  
  • Yan, S. S., Fox, M. L., Holland, S. M., Stock, F., Gill, V. J., Fedorko, D. P. (2000). Resistance to Multiple Fluoroquinolones in a Clinical Isolate of Streptococcus pyogenes: Identification of gyrA and parC and Specification of Point Mutations Associated with Resistance. Antimicrob. Agents Chemother. 44: 3196-3198 [Abstract] [Full Text]  
  • Nagai, K., Davies, T. A., Pankuch, G. A., Dewasse, B. E., Jacobs, M. R., Appelbaum, P. C. (2000). In Vitro Selection of Resistance to Clinafloxacin, Ciprofloxacin, and Trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44: 2740-2746 [Abstract] [Full Text]  
  • Swartz, M. N. (2000). Impact of Antimicrobial Agents and Chemotherapy from 1972 to 1998. Antimicrob. Agents Chemother. 44: 2009-2016 [Full Text]  
  • Guerin, F., Varon, E., Hoi, A. B., Gutmann, L., Podglajen, I. (2000). Fluoroquinolone Resistance Associated with Target Mutations and Active Efflux in Oropharyngeal Colonizing Isolates of Viridans Group Streptococci. Antimicrob. Agents Chemother. 44: 2197-2200 [Abstract] [Full Text]  
  • Betriu, C., Redondo, M., Palau, M. L., Sanchez, A., Gomez, M., Culebras, E., Boloix, A., Picazo, J. J. (2000). Comparative In Vitro Activities of Linezolid, Quinupristin-Dalfopristin, Moxifloxacin, and Trovafloxacin against Erythromycin-Susceptible and -Resistant Streptococci. Antimicrob. Agents Chemother. 44: 1838-1841 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Rieux, V., Muffat-Joly, M., Bedos, J. P., Vallee, E., Rivier, C., Isturiz, R., Carbon, C., Moine, P. (2000). Relationship between Capsular Type, Penicillin Susceptibility, and Virulence of Human Streptococcus pneumoniae Isolates in Mice. Antimicrob. Agents Chemother. 44: 1575-1577 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, P.-L.
Right arrow Articles by Seto, W.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, P.-L.
Right arrow Articles by Seto, W.-H.

Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»